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One goaloftransplantation immunology is to make possible successful tissue and
organ transplantationwithout need for long-term immunosuppression (1). To over-
come immunological barriers that include the strongest multimajor histocompati-
bility (H)1 complex antigenic barriers plus multiminor H antigenic barriers, or even
to overcome xenogeneic antigen barriers, seems urgent to clinical transplantation.
To achieve this goal, induction of a state of immunologic tolerance that includes a
stable chimerism may be one practical approach (2).
Sinceachimeric animal willaccept almost all organs from adonor ofbone marrow
cells (3-5), various methods to establish chimerism for subsequent allo- or xeno-
grafting have been reported (6-10). Despite extensive studies, understanding ofthe
cellular or molecularbasis ofimmunologictolerance in such chimeras remains enig-
matic (11-16). Mechanisms that involve clonal deletion or inactivation, or active im-
munosuppression via suppressive lymphocytes, have been debated (11-16). In spite
ofthelack ofunderstanding ofthe underlyingprocess, a practical method forinduc-
tion ofimmunologictolerance represents avalid goal. Ifalong-lasting tolerant state
that crossesthemost forbiddingbarriers between donorand recipientcouldbeachieved
withouthazard to the recipient, tissue and organ transplantation would be advanced.
Wehave reported amethod oftolerance induction in adult mice that uses intrave-
nous injection of 50-100 x 106 allogeneic donor-strain spleen cells followed, usu-
ally 2 d later, by 150-200 mg/kg ofcyclophosphamide (CP) by the intraperitoneal
route. Using this method, we have regularly established a minimal degree ofmixed
chimerismassociatedwith apparently permanent allografttolerance across a variety
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of H barriers (17, 18, Mayumi, H., and R. A. Good, submitted for publication).
However, it has not previously been possible to overcome regularly entire major H-2
plus multiminor H (fully allogeneic) barriers. Evidence suggested that this limita-
tion could be attributed to development, during the induction of the tolerant state,
of a population of cells that are resistant to CP and thus persist in a reactive rather
than tolerant state (19, 20). From our further analysis, (Mayumi, H., and R. A.
Good, submitted for publication), a less proliferative, more rapidmaturation of reactive
T cells was proposed to have occurred when the antigenic exposure was relatively
small in proportion to a large population ofpersistently reactive cells in the recipient
mice. Moreover, this less proliferative, more rapid maturation was found in prelimi-
nary studies to be eliminated by reducing the total number of reactive T cells in
the recipient mice in preliminary experiments. In another study (21) we showed that
stem cells capable of persistent replication represent a vital part of a regimen that
induces long-lasting tolerance in the system we have developed.
The aim of the present study has been to develop a tolerance induction method
that can regularly and specifically overcome fully allogeneic (entire H-2 plus mul-
timinor H antigen) barriers in mature mice using allogeneic (tolerogenic) cells ob-
tained from a single adult cadaver donor. To reduce immunocompetent T cells in
recipient mice, mAbs against T cells or antibodies (Abs) versus different subpopula-
tions of T cells were used. To enhance the tolerogenicity of spleen cells, bone marrow
cells were added to the spleen cell inoculum to provide an enriched population of
stem cells. When recipient mice were given 50-100 wg i.v. or i.p. of antiThy-1 .2 Ab
on day -1, 90 x 106 spleen cells plus 30 x 106 i bone marrow cells from fully al-
logeneic donors intravenously on day 0, and then 200 mg/kg i.p. of CP on day 2,
long-lasting skin allograft (grafted on day 15) tolerance that was associated with a
minimal degree of mixed chimerism was regularly established in each of four fully
allogeneic murine strain combinations. These manipulations could all be crowded
together in a short interval and could be adapted to use materials from a single ca-
daver for production of the long-lasting tolerant state.
Materials and Methods
Animals. Inbred Thy-1.2' female mice 8-10 wk old of BALB/cByJ (BALB;H-2d),
C3H/HeJ (C3H; H-2k), C57BL/6J (B6; H-2b), and DBA/2J (DBA; H-2d) strains (the
Jackson Laboratory, Bar Harbor, ME) were maintained in the University of South Florida
Animal Research Center, St. Petersburg, FL. Mice were provided acidified water and were
kept in sterilized cages on laminar air-flow racks.
Cell Preparations.
￿
Mice were killed by decapitation. The spleen, tibia, and femur were col-
lected and kept on ice in RPMI 1640 medium (Gibco Laboratories, Grand Island, NY). The
spleen was disrupted in the medium by pressing spleen fragments between two glass slides.
Bone marrow was flushed out using a 5-ml syringe with 25-G needle (Becton Dickinson &
Co., Rutherford, NJ). Cell suspensions were filtered through cotton gauze and washed three
times with the RPMI. Viable nucleated cells were counted and adjusted, usually to 120 x
106/ml. Viability of the cells was evaluated using trypan blue dye exclusion in the standard
way.
Tolerance Induction.
￿
Purified antiThy 1.2 (rat IgG2b), anti-Lyt-1 (rat IgG2a), anti-Lyt-2
(rat IgG2a), and anti-L3T4 (rat IgG2b) mAbs were purchased from Becton Dickinson &
Co. (Mountain View, CA). A given dose of antibody was injected intravenously or in-
traperitoneally as indicated. Usually, antibody was given 1 d before cell injection (on day
-1). A given dose of spleen cells, bone marrow cells, or a mixture of these two kinds of cells
from fully allogeneic donors was injected intravenously via the tail vein of recipient mice,MAYUMI AND GOOD
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usually 2 d before CP treatment was given (Day of the cell injection = day 0). CP (Cytoxan;
Bristol-Myers, Syracuse, NY) dissolved in PBS at a concentration of20 mg/ml was administered
in a dose of 200 mg/kg, usually 2 d after the cell injection (on day 2). In the assay to confirm
optimal timing of antibody treatment and CP treatment, the timing of these treatments was
varied as indicated (Table IV).
Skin Grafting.
￿
Using a procedure we have reported previously (22), skin grafting was car-
ried out usually 13 d after CP treatment (on day 15). Graft beds, measuring 1 cm x 1 cm,
were prepared on the right lateral thoracic wall. The panniculus carnosus was kept intact
in the graft beds. Full-thickness square grafts, 1 cm x 1 cm, were sutured to the graft beds
by eight interrupted sutures and were covered with protective tape. The first inspection of
skin grafts was done 7 d after grafting, followed by daily inspections for 3 wk and weekly
inspections thereafter. In the tolerant state, luxurious hair growth generally was observed,
with the growth ofhair beingcounterpoint to the normal hair growth and usually of different
color than the normal hair of the recipient strain. The end-point of graft rejection was rela-
tively easy to judge in both the acute state(within 30 d aftergrafting) and chronic state (later
than 30 d after grafting), because the chronic rejection in the tolerant mice started with the
loss of the hair and culminated in necrosis of the graft epithelium that was occasionally as-
sociated with ulcer formation. Therefore, in both acute and chronic rejection, the graft was
considered to have been rejected when no normal epithelium could be found on the graft
bed. Graft survival was expressed in days as mean survival time (MST) f SD.
Assay ofDelayed Footpad Reaction (DFR).
￿
DFR was elicited by injecting 0.05 ml of RPMI
containing 10' C3H or BALB spleen cells irradiated with 2,000 rad using 6,000 Ci Cesium-
137 (Mark I Model 68; JL Shepherd, Glendale, CA) into the right hind footpad of B6 mice.
Into the left hind footpad, 0.05 ml of the RPMI alone was injected. Swelling was measured
after 24 h with a dial-thickness gauge (Peacock, Kyoto, Japan). Net swelling was calculated
by subtracting swelling in the left footpad from swelling in the right footpad. The first DFR
challenge was performed 7 d after the CP treatment for tolerance induction (on day 9) to
estimate the anamnestic immune status afterthe tolerance induction, as described previously
(19, 20, 23) . The second challenge was done 7 d after the first (on day 16), concurrent with
intraperitoneal boosting for the assay of CTL activity. Therefore, the initial challenge was
used not only to elicit DFR but also to immunize the mice for a second assay of DFR and
for assays of CTL activity and antibody production.
Assay of CTL.
￿
Boosting for the CTL assay was carried out concurrently with the second
DFR challenge (on day 16) in each mouse by injecting 0.2 ml of RPMI containing 10' 2,000-
rad irradiated C3H or BALB spleen cells into the peritoneal cavity with 5 ml of RPMI 3 d
afterintraperitoneal boosting with C3H or BALB spleen cells (on day 19) . Peritoneal exudate
cells that were nonadherent to glass were prepared by incubation of unfractionated perito-
neal exudate cells in glassdishes for 1 h at 37°C, and then with gentle agitation by pipette.
These glass nonadherent peritoneal exudate cells were adjusted to 10'/ml or 5 x 106/ml in
RPMI supplemented with 10% heat-inactivated FCS (KC Biological, Inc. Lenexa, KS) and
were used as effector cells for the CTL assay. Contamination of the effector cells by macro-
phages was <10%.
Target cells were prepared by incubating B6, C3H, of BALB spleen cells at a concentra-
tion of 3 x 106/ml in the RPMI supplemented with 10% FCS containing 5 wg/ml of Con
A (Pharmacia Fine Chemicals, Uppsala, Sweden) for 2 d. 106 cells in 1 ml of the FCS were
incubated with 200 Ci of51Cr (New England Nuclear, Boston, MA) for 1 h to label the target
cells.
A standard "Cr-release assay was used in the humidified 5% COz incubator for 4 h at
37°C. The assay was carried out in triplicate in a round-bottomed 96-well microplate (No.
25850; Corning Glass Works, Corning NY) in a total volume of 0.2 ml. The labeled target
cells, 2 x 104 in 0.1 ml RPMI with 10% FCS, were added to effector cells, 1 x 106 and
0.5 x 106 in 0.1 ml. After the 4-h incubation, 0.1-ml of supernatant was harvested and
counted using a y counter (Multi-crystal gamma counter; Berthold, Wildbad, FRG). Per-
centage of specific release was calculated as follows: Percent specific lysis = 100 x [(experi-
mental release - spontaneous release) / (maximal release - spontaneous release)] . The max-
imal release was obtained by adding 0.1 ml of1% Triton X-100(Thomas Scientific, Swedesboro,
NJ) to 0.1 ml of target cells. The spontaneous release signifies the cpm released from target21 6
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cells incubated with the medium alone. The spontaneous release was <20% of the maximal
release. All values represent the mean percentage specific "Cr release of triplicate samples
t SD.
Assay ofAntibody.
￿
Sera were collected and pooled from 10 mice when the mice were killed
for the CTL assay (on day 17). The "Cr-release assay with antibody was similar to the CTL
assay described above(23), and was carried out in triplicate in microplates. The labeled cells,
2 x 104 in 0.1 ml ofthe RPMI with 10% FCS, were incubated with 0.1 ml of RPMI-diluted
sera (x 1, x 4, and x 16) for 15 min at room temperature. After adding 0.02 ml of guinea
pig complement (ICN Pharmaceuticals, Inc., Lisle, IL), the cells were incubated for 3 h more
at 37°C in the humidified 5% C02 incubator. The supernatant was harvested and counted
as well. Percentage of specific release was calculated using the equation described in the assay
of CTL. The maximal release was obtained as well as the assay of CTL. The spontaneous
release, which was <20% of the maximal release, was defined as the cpm released from the
target cells incubated only with the medium plus complement. All values represent the mean
percentage of triplicate samples ± SD.
Assay of Chimerism.
￿
The direct immunofluorescence method using FITC-conjugated anti-
H-2Kk or anti-H-2KbDb mAb (Meiji, Tokyo, Japan) was used to stain spleen cells.
Fluorescence-positive cells were measured with the FAGS (EPICS C, Coulter Corporation,
Hialeah, FL). Red blood cells among the spleen cells were destroyed bylysiswith Tris-buffered
0.83% NH4C1 before staining with the antibody. Red blood cells and dead lymphocytes were
excluded by scatter. The chimerism of each mouse was assayed separately, with data expressed
as the percentage of fluorescence-positive cells per 3,000 cells analyzed.
Statistics.
￿
When group data were parametric, one-way or two-way analysis of variance
(ANOVA) was performed first. Only when the variance was significant was the Student's t-test
performed (24). When group data were nonparametric, the Mann-Whitney U-test was used
(25). For multiple comparisons with both methods, the Bonferroni correction was used (24).
p values were calculated by means of a personal computer (PB-700; Casio, Tokyo, Japan).
A p value of <0 .05 was taken to be significant.
Results
Long-Lasting Skin Allograft Tolerance Induced Across the Entire H-2 Plus Multiminor H
AntigenBarriers. With the full protocol for inducing tolerance (Exp. 1, Table I; Group
11) a very long-lasting skin allograft tolerance to C3H(H-2k) was produced in B6(H-
26) mice. The protocol consists of injection of 100 gg i.p. of antiThy-1.2 antibody
on day -1, an injection of 90 x 106 spleen cells plus 30 x 106 bone marrow cells
from naive C3H mice on day 0, followed by an injection of 200 mg/kg i.p. of CP
on day 2 . The same results were obtained in other fully allogeneicdonor-receipient
combinations of B6-C3H (Exp. 2, Group 5), BALB(H-2d)-'B6 (Exp. 3, Group
5), and BALB-C3H (Exp. 4, Group 5) .
Tolerance was not induced when the mAb and 90 x 106 spleen cells and 30 x
106 bone marrow cells alone, but not CP, were given (Exp 1, Group 8; Exps. 2-4,
Group 4). However, an appreciable level o£tolerance, but not nearly so long-lasting
a tolerance, was induced when 90 x 106 spleen cells plus 30 x 106 bone marrow
cells and CP but no antibody, were given to the recipient (Exp. 1, Group 5 ; Exps.
2-4, Group 3). A more conventional method of tolerance induction used previously
in our studies, i.e., allogeneic spleen cells (120 x 106 rather than 100 x 106) followed
in 2 d by GP, prolonged skin graft survival only slightly in the graft exchanges be-
tween these most disparate strain combinations (Exp. 1, Group 3; Exps. 2-4, Group 2).
Other groups treated in various ways were set up as controls in the donor-recipient
combination of C3H-"B6 (Exp. 1). Among these controls, neither CP alone (GroupMAYUMI AND GOOD
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2), 30 x 106 bone marrow cells plus CP (Group 4), antibody alone (Group 6), nor
antibody plus CP (Group 7) prolonged graft survival. Moreover, treatments with
antibody 120 x 106 spleen cells, plus CP (Group 9) induced only a slight degree
of tolerance. Treatments with antibody, 30 x 106 bone marrow cells, and CP (Group
10) induced tolerance (MST = 53.0 d), but again this fell short of the more persis-
tent tolerance induced by the full regimen (MST = 117.7 d), which in most mice
produced a tolerant state that lasted as long as the experiments to test its persistence
were carried out.
The specificity of the persistent tolerant state induced by this methodology was
tested in the C3H-B6 and B6-C3H combinations. Tolerance induced in B6(H-
26) mice with antibody, 90 x 106 spleen cells plus 30 x 106 bone marrow cells from
C3H(H-2'), and CP was specific to C3H since third-party skin from DBA(H-2d)
was rejected in the tolerant mice with a normal tempo (Exp. 1, Group 13). In the
reciprocal fully allogeneic combination ofB6-C3H, the same resultswere obtained
in the mice subjected to the full tolerance-inducing regimen (Group 7; Exp. 2).
Dose-Response of anti-Thy-1.2 Antibody in Tolerance Induction in B6 Mice.
￿
In the
donor-'recipient combinationofC3H-B6, dose-response to antiThy-1.2 antibody
was examined (Table II). AntiThy 1.2 antibody in a dose range of 12.5-100 gg was
given intraperitoneally to the recipient B6 mice on day -1, followed by 90 x 106
spleen cells plus 30 x 106 bone marrow cells from C3H on day 0, and CP on day
2. The graft survival in the groups that received 12.5 gg (Group 3), 50 gg (Group
5), or 100 gg (Group 6) of antibody, C3H cells, and CP was significantly longer
compared with that in a group that was given C3H cells plus CP, but not antibody
(Group 2). These groups, however, did not show significant differences from one
another. When 200 gg (0.8 ml) of the antiThy-1.2 antibody was injected in-
traperitoneally, the recipient B6 mice died. The quick death observed in this experi-
ment was possibly attributable to sodium azide that was contained in the antibody
preparation as preservative. Therefore, 100 gg (0.4 ml) was found to be the max-
imum dose of this antibody tolerated by the intraperitoneal route. Moreover, when
the antibody was given intravenously, 50 gg (0.2 ml) was the maximal dose regu-
larly tolerated. After conducting these experiments, dosages of 100 gg i.p. or 50 gg
i.v. of the antibody were used in the tolerance-inducing regimen as indicated.
Dose-Response of C3H Bone Marrow Cells in Tolerance Induction in B6 Mice.
￿
In this
experiment (Table III), dosages between 1 and 100 x 106 C3H bone marrow cells
were injected into B6 mice together with or without 100 x 106 C3H spleen cells,
and these cellular injections were administered with or without prior injection of
50 gg i.v. of antiThy 1.2 antibody.
As shown in Groups 3 and 5, tolerance induction was clearly dependent on the
dose of bone marrow cells given. By contrast, when an inappropriately small dose
ofbone marrow cells hadbeen given (Group 4), skin graft survival was further short-
ened as compared with untreatéd normal control mice (Group 1).
The tolerance induced with 1-100 x 106 bone marrow cells plus CP was made
more profound when 100 x 106 spleen cells were added to the dosage of bone
marrow cells given (Groups 6-8), but this effect only slightly prolonged skin graft
survival. By pretreatment with 50 gg i.v. of antiThy 1.2 antibody, however, graft
survival was greatly increased (Groups 9-11).218
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TABLE III
Dose-Response to C3H Bone Marrow Cells in Tolerance Induction in B6 Mice
* Grafting on day 15.
t p = 0.0180 compared with Group 1 by the U-test.
§ p = 0.0180 compared with Group 2 by the U-test.
When the tolerogenicity of 100 x 106 spleen cells and 100 x 106 bone marrow
cells wascompared (Group 2 vs. Group 5), thebone marrow cells proved to be much
more tolerogenic than the spleen cells.
Optimal Timing ofAnti-Thy-1.2 Antibody and CP Treatments in Tolerance Induction in B6
Mice. In priorstudies we (26, 27)and others (28-31)had tested the optimal timing
of CP treatmentto induce tolerance. This was shownto be 1-3 dafterantigen stimu-
lation. Under the influence of antibody treatment, however, the optimal timing of
CP treatment may be changed (32) . In this experiment, the antiThy-1.2 antibody
was first used before the cell injection to achieve preparatory reduction of im-
munocompetent recipient T cells. Timing of antiThy-1.2 antibody treatment was
also tested here (Table IV).
When 50 ug of antiThy 1.2 antibody on day -1, and 90 x 106 spleen cells plus
30 x 106 bone marrow cells from C3H donors were given on day 0 to B6 mice fol-
lowed by CP treatment on day 0, 1, 2, 3, 4, or 5 (Groups 4-9), profound tolerance
was induced only when CP was given on day 1, 2, or 3 (Groups 5-7).
When the antibody was given after the cell injection, i.e., C3H spleen cells plus
bone marrow cells on day 0 followed by both antibody and CP on day 2 (Group
3), long-lasting tolerance was induced, as was the case for the group in which the
antibody was given before the cell injection (Group 6).
Hereafter, theprotocol fortoleranceinduction in the present experimentsis always
an initial antibody treatment on day -1, a second injection of tolerogenic cells on
day 0, and a final CP treatment on day 2.
Complete andSpecific Abrogation of VariousImmune Responses in B6 Mice Made Tolerant
ofC3H with Anti-Thy-1.2Antibody, C3HSpleen Cells, plus C3H BoneMarrow Cells, and
then CP. Previously (19, 20, 23), we have shown that T cells mediating DFR are
most resistant to tolerance induction with 50-100 x 106fully allogeneic spleen cells
plus 150-200 mg/kg CP, and are probably responsible for skin graft rejection (19,
20, 23) anddevelopment ofgraft-vs.-host disease(17). Moreover, the T cells remained
Anti-Thy-1 .2
antibod
C3H
(106.
cells
i .v.,
CP (200
mg/kg,
(50 kg, i .v., on day 0) i . Survival of C3H skin graft No. of
Group on day - 1) SC BMC on day 2) (days)* mice MST + SD
1 - - - - 10, 10, 10, 11, 12 5 10.6 + 0 .9
2 - 100 - + 10, 5 11 .2±0.8
3 - - 1 + 9, 9, 10, 11, 12 5 10.2 ± 1 .3
4 - - 10 + 8, 8, 9, 9, 9 5 8 .6 ± 0 .5t
5 - - 100 + 16, 17, 30, 54, >103 5 >44.0 ± 36.44
6 - 100 1 + 11, 5 12 .0+1 .7
7 - 100 10 + 10, 13, 15, 19, 29 5 17 .2 ± 7.4
8 - 100 100 + 16, 16, 17, 39, >103 5 >38.2 ± 37 .5
9 + 100 1 + 11, 13, 13, 29, 39 5 21 .0 ± 12.4
10 + 100 10 + 23, 60, 67, 74, 88 5 62 .4 + 24.3
11 + 100 100 + 46, >102, >102, >102, >102 5 >90.8 + 25 .0222
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TABLE IV
Optimal Timing of anti-Thy-1.2 Antibody and CP Treatments in
Tolerance Induction in B6 Mice
C3H cells
* Grafting on day 17 .
1 p < 0.05 compared with Group 1 by the U-test .
in a sensitized state after tolerance induction, probably because a less proliferative,
more rapid maturation occurred in some T cells during the 2-d interval between
antigen stimulation and CP treatment, while most ofthe reactive cells appeared to
be destroyed via an antigen-stimulated proliferating cell destruction by CP.
Usingvarious immunological parameters, weexamined and compared the tolerant
state in B6 mice induced conventionally with 120 x 106 C3H spleen cells and 200
mg CP, and that induced by our new method with 50 ug of antiThy-1.2 antibody
(intravenously), 90 x 106 C3H spleen cells plus 30 x 106 bone marrow cells, and
200 mg/kg CP.
As shown in Table V, the first challenge to elicit DRF 7 d after the CP treatment
was used to estimate the existence of memory T cells after tolerance induction. In
the B6 mice given 120 x 106 C3H spleen cells and CP (left column; Group 3), there
was a weak but significant level offootpad swelling as compared with negative con-
trols (left; Group 2). In the B6 mice made tolerant of C3H with the antibody,
90 x 106 spleen cells plus 30 x 106 bone marrow cells, and CP, however, no residual
response could be found (left; Group 4). Using this first challenge for immuniza-
tion, a second challenge with allogeneic cells to elicit DFR was performed 7 d later.
In positive controls (right; Group 2), a strong response to C3H antigen was ob-
served. In the B6 mice treated with C3H spleen cells and CP (right; Group 3), a
moderate degree of response was achieved as compared with the negative controls
(Group 1). This response was weaker than that ofthe positive controls (Group 2).
In the B6 mice given antibody, spleen cells plus bone marrow cells, and then CP
(right; Group 4), a DFR was not detectable.
In these tolerant B6(H-26) mice given antibody, C3H(H-2k) spleen cells plus bone
marrow cells, and CP, however, the DFR to a third-party antigen from BALB(H-
2d) was normal (Group 7). Therefore, the tolerant state in the B6 mice was shown
to be tolerogen specific.
Assays ofCTL activity (Table VI) and antibody production (Table VII) showed
similar patterns ofresponses. In the B6 mice given antibody, C3H spleen cells plus
Group
Anti-Thy-1 .2
antibody
(50 wg; i.v.,
on day X)
(90x106 SC
+ 30x 106
BMC, i .v.,
on day 0)
CP (200
mg/kg;
i.p. on
day Y)
Survival of C3H skin graft
(days)*
No. of
mice MST ± SD
1 - - - 9, 9, 10, 10, 10 5 9 .6 ± 0 .5
2 - + +2 17, 21, 22, 49, >98 5 >41 .4 ± 34.1t
3 + 2 + + 2 70, 98, >98, >98, >98 5 >92.4 ± 12 .51
4 - 1 + 0 8, 9, 9, 10, 10 5 9 .2 ± 0 .8
5 - 1 + + 1 49, 63, 63, 70, 77 5 64.4 + 10 .31
6 - 1 + + 2 42, >98, >98, >98, >98 5 >86.8 t 25 .0~
7 -1 + +3 23, 49, 84, 91, >98 5 >69.0 ± 31 .9"
8 - 1 + + 4 9, 9, 10, 10, 10 5 9 .6 t 0.5
9 - 1 + + 5 9, 10, 10, 10, 11 5 10.0 ± 0 .7ü
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C3H bone marrow cells, and then CP, CTL activity (Table VI, Group 4) and anti-
body production (Table VII, Group 4) against the tolerogen were completely
abrogated. In the B6 mice given C3H spleen cells plus CP, both responses (Tables
VI and VII; Groups 3) against the tolerogen also were almost completely abrogated,
but a statistically insignificant level ofweak response was recorded (second column) .
Although cross-suppression could be demonstrated to some extent as compared
with the positive controls (Tables VI and VII, Groups 6), CTL activity (Table VI,
Group 7) and antibody production (Table VII, Group 7) against third-party BALB
(H-2d) targets were observed in the B6 (H-26) mice made tolerant of C3H (H-2k)
with antibody, C3H spleen cells plus bone marrow cells, and then CP. Moreover,
crossreactions of positive controls to third-party targets were observed to some ex-
tent in both the CTL assay (Table VI, Groups 2 and 6) and the antibody assay (Table
VII, Groups 2 and 6). However, no response to syngeneic (B6) targets occurred in
any of the groups examined (Tables VI and VII, Groups 1-7).
Chimeric Analysis in B6 Mice Made Tolerant of C3H .
￿
To analyze further the mecha-
nisms of tolerance, the existence of mixed chimerism in the B6 mice made tolerant
of C3H with 100 wg of antiThy 1 .2 antibody (intraperitoneally), 90 x 106 C3H
spleen cells plus 30 x 106 bone marrow cells, and then CP was examined (Table
VIII). This seemed important because in other experiments in the series a minimal
degree of mixed chimerism seemed a prerequisite for maintaining prolonged skin
allograft tolerance in the system developed (17, 18).
In the B6(H-26) mice made tolerant of C3H(H-2k) by the antibody, C3H spleen
cells, bone marrow cells, plus CP regimen, a small number of H-2 Kk+ cells of
donor (C3H) origin were regularly detected among the recipient B6 spleen cells,
and the proportion of H-2KbDd+ cells of recipient origin was decreased slightly
(Group 5) when the assay was done 1 mo after the tolerance induction. This min-
imal degree of chimerism in the tolerant B6 mice was also observed 2 mo after the
tolerance induction, although the reciprocal reduction of H-2KbDb+ cells of recip-
ient origin was statistically insignificant (Group 5). In the B6 mice made tolerant
One-way ANOVA among Groups 2-5 ;
p value
TABLE VIII
Chimeric Analysis in B6 Mice Made Tolerant of C3H
<0.0001
￿
<0.0001
￿
= 0 .0002
￿
= 0.1363
SC, spleen cells .
* The recipient B6 mice were made tolerant of C3H with 120 x 106 C3H spleen cells on day 0 and CP on
day 2 (Group 4), or with 100 pg of anti-Thy-1 .2 antibody (i.p.) on day - 1, 90 x 106 C3H spleen cells
plus 30 x 106 bone marrow cells on day 0, and CP on day 2 (Group 5) .
1 Not significant compared with Group 2 by the t test .
4 p < 0.001 compared with Group 2 by the t test.
EPICS analysis: Percent positive cells ± SD (n = 5)
Group Recipient* (pretreatment) H-2K
On day
k
33
H-2KbDb H-2K
On
k
day 62
H-2KbDb
1 C3H (untreated) 94.5 ± 2.2 0.7 ± 0.2 90.1 ± 1 .3 1 .0 ± 0.5
2 B6 (untreated) 0.4 ± 0.1 94.5 ± 0.6 0.4 ± 0.1 83 .2 ± 7.4
3 B6 (CP alone) 0.3 +_ 0.1 94.0 +_ 0.6 ND ND
4 B6 (SC/CP) ND ND 0.6 + 0.2t 84.5 + 4.4
5 B6 (antibody/SC + BMC/CP) 3 .0 ± 0.84 89.3 ± 0.95 3.2 ± 1.44 75.8 ± 8.1MAYUMI AND GOOD
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of C3H with 120 x 106 C3H spleen cells followed by CP, such stable chimerism
was not established (Group 4).
Tolerance Induced in B6 Mice with antiThy-1.2 Antibody, C3H Spleen Cells Plus C3H
Bone Marrow Cells, andCPIs Attributable to Reduction ofEffector Cells. Transfer experi-
ments were carried out to test the mechanisms oftolerance induced by the present
method (Table IX). Tolerance to C3H was induced in B6 mice with 50 ug i.v. of
antiThy-1.2 antibody, 90 x 106 C3H spleen cells plus 30 x 106 bone marrow cells,
and then CP. 2 wk later, naive 136 mice and the tolerant B6 mice were grafted with
C3H skin. 108 million spleen cells and 0.3 ml of serum from the tolerant 136 mice
were transferred into naive B6 mice that had been grafted on the same day with
C3H skin(Group 3). Prolongation ofC3H skin graft survival wasnot observed (Group
3), indicatingthat demonstrable tolerance was not transferred from the tolerant B6
into the naive 136 mice. On the other hand, when 100 x 106 naive B6 spleen cells
were transferred into the tolerant B6 mice that had been grafted on the same day
with C3H skin (Group 4), the C3H skin was rejected in a normal fashion in the
tolerant B6 mice, indicatingthattolerancewas readily abrogatedby the cell transfer.
These results suggest that the main mechanism responsible fortolerance in this system
is reduction ofeffector cells rather than a form ofactive suppression. These results,
however, cannot exclude the existence ofa weak level of suppressive cell and/or sup-
pressive serum action in the tolerant mice.
Tolerance Inducibility of VariousAntibodies in B6 Mice.
￿
Results from our in vivo (19,
20, 23, 26) and in vitro (33, 34) experiments and data presented herein (Table V),
show that T cells mediating DFR and helper T cells, both of which are known to
have L3T4 (CD4) markers (35), are the cells that are most resistant to tolerance
induction. To further test this interpretation, various mAbs were used to induce toler-
ance in B6 mice (Table X). Although all ofthe antibodies used in these experiments
were rat IgGantibody, differences ofaffinities may exist amongthe antibodies used;
also, no evidence that the recipient B6 mice were saturated with the different anti-
bodies used or equally suppressed with the amountofantibodies used was obtained.
To analyze these data as objectively as possible, two different doses (50 ug in 0.2
TABLE IX
Tolerance Induced in B6 Mice with anti-Thy-1.2 Antibody, C3H Spleen Cells plus
Bone Marrow Cells, and CP Is Attributable to Reduction of Effector T Cells
' The B6 mice were given 50 jig of anti-Thy-1 .2 antibody i.v. on day - 1, 90 x 106 C3H spleen cells plus
30 x 106 bone marrow cells i.v. on day 0, and 200 mg/kg CP i.p. on day 2.
$ p = 0.0271 compared with Group 1 by the U-test.
5 Not significant compared with Group 1 by the U-test.
Group
Recipient
(pretreatment)
Transferred cells
and serum (on the
day of skin grafting)
Survival of C3H
skin graft (days)
(grafting on day 15)
No. of
mice MST t SD
1 B6 (untreated) - 9, 10, 11, 12, 13 5 11.0 t 1 .6
2 B6 (tol. to C3H)" - >75, >75, >75, >75, >75 5 >75.0 t O.Ot
3 B6 (untreated) 1o0 x 106 SC + 0.3
ml serum from B6
(tol. to C3H)' 9, 10, 10, 12, 12 5 10.6 t 1.35
4 B6 (tol. to C3H)' 100 x 106 SC from
B6 (untreated) 10, 11, 11, 12, 12 5 11.2 t 0.85228
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ml and 25 ug in 0.1 ml) were used. For anti-L3T4 antibody, the doses of 10 ug in
0.2 ml, 5 ug in 0.1 ml, and 2.5 gg in 0.05 ml were used. These antibodies were given
intravenously on day -1, followed by 90 x 106 C3H spleen cells plus 30 x 106 bone
marrow cells on day 0, and CP on day 2.
The longest survival was achieved when the B6 mice were treated with 50 gg or
25 wg of antiThy-1.2 antibody (Groups 3 a and b) or 10 tLg of anti-L3T4`antibody
(Group 6 a). Both anti-Lyt-1 antibody and anti-Lyt-2 antibody appeared to have
some influence to facilitate tolerance induction, but the effect of the latter two anti-
bodies was slight (Groups 4 and 5). The addition of 50 gg of anti-Lyt-2 antibody
to 10 ug of anti-L3T4 antibody may have exerted an additive effect, but this influence
was not impressive (Group 7), even though the number of mice in this group was
quite small.
Discussion
Usingthreetreatmentcomponents administered within a 3-d period, namely anti-
Thy-1.2 antibody (or anti-L3T4antibody), allogeneic spleen cells plus bone marrow
cells, and CP, we regularly induced very long lasting skin allograft tolerance across
fully allogeneic (all known H-2 components plus multiminor H) antigen barriers
in each of four murine combinations examined (Table I). Since the tolerogenic cell
doses used can be obtained from a single donor mouse, and since the total dose of
200 mg/kg CP used was quite tolerable for mice and did not require subsequent
hematopoietic reconstruction, the strategy used can be considered to be one that
is possibly adaptable to other species, e.g., lower primates and even man. Indeed,
a comparable dose of CP given over 3 d is tolerated by monkeys (36). A maximal
use of anti-T cell or anti-CD4 antibody before (Tables I-X), during, and/or after
(Table IV) tolerance induction might furtherreduce the amount of CP needed. This
issue should be examined experimentally first in lower primates.
The clues that led to the development of thepresentpotentially practical protocol
forregularly inducing long-lasting tolerance during adultlife were derived from our
earlier studies (17-23, 26, 27). First we showed that tolerance to a large allogeneic
tumor inoculum, but not to a small dose of tumor cells or to a skin allograft, can
be achieved with 50-100 x 106 viable fully allogeneic spleen cells followed by
150-200 mg/kg CP (19, 20, 23, 26). The tolerant state achieved by this combined
treatment with spleen cellsplus CP that uses thespleen cells as antigenic stimulation
to induce cell proliferation permits later destruction of the proliferating cells with
CP. Although it was a form of split tolerance, it was induced across fully allogeneic
antigen barriers in which resistance to more complete tolerance appeared to be at-
tributable to a relatively small proportion of less proliferative T cell clones or to a
rapid maturation of T cells to a CP-resistant state without their becoming vulner-
able as when proliferation occurs (19, 20, 23). Since permanent skin allograft toler-
ance could regularly be induced across multiminor H antigen disparities (27, 37)
and also quite easily across the H-Y antigen barrier (38) with 150-200 mg/kg CP,
the dose of CP was considered to be sufficient. To increase the dose of the spleen
cells to >100 x 106 was considered impractical because this appeared to be the max-
imal dose of spleen cells that could be collected from a single donor mouse at one
time. Therefore, attempts to change theless proliferative mode of immune response
into a more uniformly proliferative mode that might render the reacting cells sus-230
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ceptible to CP were made by a variety ofmethods(23, 39, 40). However, permanent
or very long lasting skin allograft tolerance across fully disparate MHC plus mul-
timinor allogeneic barriers was not achieved by the manipulations (23, 39, 40).
Studies to test sensitivity to tolerance induction using congenic strains of mice
(Mayumi, H., and R. A. Good, submitted for publication) revealed that resistance
(or less proliferative maturation of reactive T cells) to tolerance induction across
fully allogeneic barriers is generated by cumulative influences on the recipient T
cells that are reactive against donor class I, class II, or multiminor H antigens.
Moreover, induction ofsemipermanent skin grafttolerance with normal hair growth
across fully aflogeneic barriers was achieved using a two-step induction method in
which the frequency of recipient T cells reactive at any one time was reduced by
using stimulatingspleen cells from congenic mice as a first-step tolerogen (Mayumi,
H., and R. A. Good, submitted for publication). This study suggested that an anti-T
cell antibody might be used as a preparatory step to reduce the reactive T cells in
the recipient. Furthermore, in another series of studies, it appeared that stem cells
contained in the tolerogenic spleen cell inoculum might play a critical role in estab-
lishing a stable tolerant state (21). Therefore, bone marrow cells were added to the
spleen cell inoculum in an effort to boost tolerogenicity by boosting thedose of stem
cells in the present study.
As shown in Table 1, a very long lastingand often impressively persistent tolerant
state was induced only when all ofthe threecomponents ofthe treatment were used:
first antibody, then spleen cells plus bone marrow cells, and finally a single large
dose of CP. However, spleen cells plus bone marrow cells and CP (Exp. 1, Group
5; Exps. 2-4, Group 3), or antibody, bone marrow cells, and CP (Exp. 1, Group
10) induced a significant degree of tolerance without the mAb. This finding sug-
gested that the bone marrow cells contribute significantly to the induction of the
tolerant state. The tolerogenic capability of bone marrow cells was examined both
qualitatively and quantitatively (Table III) andwas found to make a greater contri-
bution to long-lasting tolerancethan didtheviabilityofthe spleen cells. There seemed
little doubt that antiThy-1.2 antibody contributed to tolerance induction, as was
shown in various fully allogeneic combinations (Tables I and III), and this point
was confirmed quantitatively (Tables II and X). The role of spleen cells as an effec-
tive source of antigen that can evoke proliferation of reactive T cells (21) appeared
to be confirmed in the present study by comparing Groups 4 and 5 (Table L, Exp.
1), Groups 10 and 11 (Table I, Exp. 1), or Groups 3-5 and Groups 6-8 (Table III) .
Other possible explanations fortolerance induction in the present study were dis-
missed by the several control groups included in Table I. For example, the tolerance
might have been induced simply because of the increment in the number oftolero-
genic spleen cells from 100 x 106 (17, 23, Mayumi, H., and R. A. Good, submitted
for publication) to 120 x 106. But this was found not to be the case (Exp. 1, Group
3; Exps. 2-4, Group 2). With CP alone (Exp. 1, Group 2) or with antibody alone
(Exp. 1, Group 6), tolerance was not produced. The possibility that the influence
ofthe ratIgG (antiThy-1.2)antibody was prolonged because of thetoleranceinduc-
tion against the antibody itself with CP (41) could be excluded (Exp. 1, Group 7).
Moreover, the possibility that the tolerance was induced with antibody plus lym-
phoid cells alone but notwith CP (6, 42, 43) was excluded in all of thecombinations
examined (Exp. 1, Group 8; Exps. 2-4, Group 4).MAYUMI AND GOOD
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Optimal timing of CP treatment was reevaluated in view ofWood and Monacds
report (32) that the optimal timing of CP treatment in theirprotocol of antilympho-
cyte serum injection, skin grafting, and then bone marrow injection was 5 d after
bone marrow injection. In anotherseries (38), we have shown that when thenumber
of reactive T cells is small, the optimal timing of CP treatment tends to be more
delayed. Since on theoretical grounds we used the antibody to reduce the number
of reactive T cells in the recipients, one might have expected some delay ofoptimal
time for the CP treatment. Contrary to ourexpectation, however, the optimaltiming
of the CP treatment was found to be 1-3 d after the cell injection, just as had been
found in previous analyses (26, 27, 33). It may not be surprising that the antiThy-
1.2 antibody was effectiveeven when theantibody had been given concurrently with
CP; i.e., 2 d after the cell injection. This observation suggests the possibility that
the antibody may exert an action to destroy T cells that usually remain after toler-
ance induction with spleen cells plus CP (19, 20, 23, and Table V).
In the B6 mice made tolerant of C3H with antiThy-1.2 antibody, C3H spleen
cells plus bone marrow cells, and then CP, a minimal degree of mixed chimerism
was established (Table VIII), and all immune parameters representative of specific
immunity that were examined appeared to be completely abrogated (TablesV-VII) .
These results are consistent with the observation ofthe very long skin graft survival
in the tolerant mice (Tables I-IV, IX, and X). By contrast, in the B6 mice made
tolerant of C3H by injections of C3H spleen cells plus CP, a weak level of DFR
remained after tolerance induction (Table V), even though CTL activity and anti-
body production were quite impressively abrogated (Tables VI and VII). In this
group, neither mixed chimerism (Table VIII) nor apparently permanent skin al-
lograft tolerance (Tables I and III) was established.
We added bone marrow cells to increase the number of stem cells and to facilitate
the establishment of chimerism as discussed above. However, normal adult bone
marrow is known to contain natural suppressor cells (11, 44) or natural suppressor
cell activities (45), and also to contain what have been called veto cells (46). It is
possible that such populationsmay have contributed to the establishment ofthe chi-
meric state. Moreover, in spite of the establishment of a mixed chimerism, there
wasno sign ofgraft-vs.-host disease in thetolerant recipient mice in thepresent system.
To establish and maintain this state of stable mixed chimerism, the role of the anti-
Thy-1.2 antibody appeared to be crucial, as was a role forCP presumably to destroy
both recipientT cellsreactive against donorantigens and donorTcellsreactive against
recipient antigens, because eventually lethal graft-vs.-host disease occurred in B6
mice (10/10) that were given antiThy-1.2 antibody, AKR/J (H-2k; Thy-1.1) spleen
cells, and then CP (Mayumi, H., and R. A. Good, unpublished data), suggesting
that the anti-T cell antibody suppressed not only the recipient T cells but also the
donor T cells in the present system .
In the transfer experiments reported here (Table IX), we could not detect any
strong suppressive influences that mightprolongskin allograft survival directly (Group
3). Moreover, the tolerant state was readily abrogatedby transferring syngeneicnaive
spleen cells to the tolerant recipients (Group 4). Theseresultssuggest that the mech-
anism of tolerance induction and maintenance in the present scheme is largely at-
tributable to reduction of effector T cellsthat are reactive againstthetolerogen, whether
the mechanism to generate this state involves active clonal deletion, clonal inactiva-232
￿
CYCLOPHOSPHAMIDE-INDUCED TOLERANCE IN ADULT MICE
tion, or clonal abortion in which reactive clones are eliminated or are rendered in-
capable ofdevelopment by an encounter with the antigens, or whether effector T
cells are suppressed and thus prevented from generating such clones ofcells (11-16).
The present method to establish a stable tolerance with a minimal degree of mixed
chimerism across fully allogeneic (entire H-2 plus multiminor H) antigen barriers
once allthreecritical ingredients are inplace seemsquitesimple andis highly repro-
ducible. It thus may provide an appropriate model for future investigations which
will permit analyses and ultimate understanding ofthe cellular and molecularbasis
orbases that underlie establishmentand maintenance oftolerance in chimeric adult
animals.
The actual cells that mediate graft rejection in mice are a subject ofsome debate.
Loveland et al. (47) reported that Lyt-1+ cells mediate skin graft rejection (47).
However, extensive studies using congenic strains of mice in both skin graft trans-
plantation (48-51) and bone marrow transplantation (51-54) have clarified that re-
jection ofclass I and class II antigens is largely mediated by Lyt-z+ and L3T4+ T
cells, respectively, while rejection of multiminor H antigens may be mediated by
either ofthe two major T cell subsets, depending on the strain combinations used.
Our previous (17, 19, 20, 23, 26, 34, 40) and present (Table V) studies consistently
appear to indicate that T cells (probably L3T4+) that also can mediate DFR are
primarily responsible for rejection of skin allografts and for causing graft-vs.-host
reactions in fullyallogeneic murine combinations. Thisconclusionseemstobestrongly
supported by our final experiment (Table X). Despite a smaller dose ofthe L3T4
(CD4) antibody used, this antibody showed a potent action to facilitate tolerance
induction (Group 6). This result to date remains limited to the C3H-B6 combina-
tion. To our surprise, however, not only anti-Lyt-2(CD8) antibody but also anti-
Lyt-1(CD5) antibody was less effective than the anti-L3T4 antibody in promoting
tolerance induction. Further studies to permit qualitative conclusions applicable to
other mouse strains are surely required.
A number ofother investigators have achieved anapparent tolerant state sufficient
to permit very long lasting skin allograft tolerance in mice just as described herein .
The impressive initial results with total nodal irradiation plus bone marrow trans-
plantation havenotbeen readily extendedtolarger animals and may havebeen difficult
to generalize in mice; further, the mechanism of tolerance in this instance appar-
entlyinvolves astrong nonspecificsuppressive action oflymphoidcells and thusseems
very different from the tolerant state described herein (7, 55). Wood and Monaco
have been struggling for some time to develop a system ofimmunological tolerance
that might ultimately be applied to larger animals and even to man (32, 56, 57).
In the first system, they have described tolerance that was achieved by treatment
with antilymphocyte serum (ALS). This method used the donor-recipient com-
bination of A-C3H, which represents a partial match at the MHC. In addition,
(C3H x A)F, spleen cells (a haploidentical system) were used in large numbers to
facilitate tolerance induction. Thus for several reasons, not the least of which are
the use of adult thymectomy and the employment of F, cells, their strategy could
not be the basis for development of a method that might ultimately be clinically
useful. The next model these investigators explored was based on a method used
by Lance and Medawar (42). In this model, CP was used both before or after the
bone marrowcelltreatment (32), and when CPwas given 1-7 dafterthe bone marrow
cells, graft survivalwas significantlyprolonged. Amajordifference between this ap-MAYUMI AND GOOD
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proach and the method we used is in the timing of the test skin graft. Monaco et
al. showed that if skin grafting was done after bone marrow cell injection, tolerance
was not induced (56, 57). In this system, the allogeneic skin graft itself apparently
contributed in some crucial way to the tolerance induction. In the system we have
described herein, once tolerance is induced with antiThy-1.2 antibody then spleen
cells plus bone marrow cells followed by CP, timing of the test skin allograft is not
of importance, and the graft appears to play no role in the induction of the tolerant
state. Thus, it is clearthat the difference between the protocol ofWood and Monaco
and that described herein is not only that we have used an mAb rather than ALS,
but also that we have used a combination of manipulations that do not depend on
the organ or tissue graft used for a contribution to the tolerance induction.
Relatively recent investigations by Ildstad et al. (51, 58, 59)in which a stable mixed
chimerism is established by a combinationofbone marrow transplants ofT cell-purged
syngeneicplus T cell-purgedallogeneic marrow have been shown to induce atolerant
state without producing graft-vs.-host reaction. This method permits development
of a tolerant state that, like the one we have produced herein, is associated with a
stable mixed chimerism and long-lasting tolerance that can bridge differences all
across the entire MHC. Thus far, however, this method hasnot permittedskin trans-
plantation across entire H-2 plus multiminor barriers (C3H-B10)without chronic
skin graft rejection. Although the difficulty with chronic skin graft rejection was at-
tributed to skin specific alloimmunity (60, 61), skin graft rejection did not appear
to be a problem after production of tolerance by the method described herein.
Bone marrow transplantation after which theanimalsaremaintained in a specific
pathogen-free environment or, in separate experiments, in a clean but conventional
environment, has also been used to produce an impressive state of tolerance that
permits regular allotransplantation of skin (62, 63), liver (64), and even pancreas
(65) without rejection. In this model recipients have been shown to be tolerant of
donor, tolerant of recipient, and fully reactive to third-party in T cell-mediated re-
sponses. However, mice tolerized by bone marrow transplantation in some systems
have exhibited an immunodeficiency leading to high morbidity and high mortality
(66, 67) when the mice are moved from laminar air flow gnotobiotic environments
to more conventional environments. The BMT tolerance model has also been as-
sociated with demonstrable immunologic deficits that have in some systems limited
fully vigorous immunologic responses in therecipients. This deficit has been shown
to be attributable to deficient interactions of donor and recipient cells (62, 63, 68).
Although this deficit is not as devastating as was originally presumed (62, 69), it
represents a limitation nonetheless (70). The advantage of the method of tolerance
induction we have described herein and also an alternative method described previ-
ouslyby Ildstad et al. (51, 58, 59) is the possibility that either ofthesemethods might
be adaptableto tolerance induction in lowerprimates or even ultimately in humans.
Future attempts to adapt tolerance-producing strategies to lower primates and to
humans based on modifications ofone ofthesetwo different models now seem much
in order.
Summary
A newmethod of cyclophosphamide (CP)-induced skin allograft tolerance in mice
that can regularly overcome fully allogeneic (major H-2 plus non-H-2) antigen bar-
riers in mice has been established. The components of the method are intravenous234
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or intraperitoneal administration of 50-100 ug of antiThy-1.2 mAb on day -1, in-
travenous injection of 90 x 106 allogeneic spleen cells mixed with 30 x 106 al-
logeneic bone marrow cellsfrom the same donoron day0, andintraperitonealinjec-
tion of 200 mg/kg CP on day 2. In each of four fully allogeneic donor- recipient
combinations, including C3H/HeJ (C3H; H-2k)-C57BL/6J(B6; H-26), B6-C3H,
BALB/cByj (BALB; H-2d)-B6, and BALB- C3H, long-lasting survival of skin al-
lografts was induced in most of the recipient mice. The specific tolerant state in-
duced was dependent on the doses of the antibody and bone marrow cells used. The
optimal timing of CP treatment to induce tolerance was found to be 1-3 d after the
stimulating cell injection. Treatment with the antiThy-1.2 antibody together with
CP on day 2 after the cell injection on day 0 also induced profound tolerance. In
the B6 mice made tolerant of C3H with antibody, C3H spleen cells plus C3H bone
marrow cells, and then CP, a minimal degree of stable mixed chimerism was estab-
lished and the antitolerogen (C3H) immune responses examined here, including
delayed footpad reaction (DFR), CTL activity, and capacity for antibody produc-
tion against donor-strain antigens were abrogated in a tolerogen-specific manner.
From cell transfer experiments, the mechanism of tolerance could be largely attrib-
uted to reduction of effector T cells reactive against the tolerogen, and strong sup-
pressive influences that might prolong skin allograft survival directly were not de-
tected in the tolerant mice. Moreover, pretreatment with antiThy-1.2 antibody or
anti-L3T4 (CD4) antibody was more effective than pretreatment with anti-Lyt-1
(CD5) antibody or anti-Lyt-2 (CD8) antibody as an initial step in tolerance induction.
These results suggest that permanent tolerance to fully allogeneic skin grafts may
be induced because antibody given before the stimulating cell injection reduces the
number ofreactive T cellsin the recipientmice. This antibody treatment mayfacili-
tate an antigen-stimulated destruction ofresponding and thus proliferating cells with
CP by preventing a possibly less proliferative, more rapid maturation of reactive
Tcells or by destroying residual effector T cells. The injection ofbone marrow cells
mixed with spleen cells appears to have facilitated maintenance of the tolerant state
by establishing a state of stable mixed chimerism in the tolerant mice.
This methodology, which induces within a very shortinterval along-lasting tolerant
state in immunologically mature mice, may possibly be adaptable to production of
full immunological tolerance across major plus minor histocompatibility barriers
in other mature mammals, e.g., lower primates and even humans. If this proves to
be the case, it could greatlyfacilitate organ transplantation without the need to con-
stantly depress immunologic reactivities, as is now needed in the practice of organ
and tissue transplantation in humans.
Received for publication 31 March 1988.
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